听力损失和阿尔茨海默病病理学之间没有纵向关联
Jordi H C Boons1, Phuong Thuy Nguyen Ho2, Anna van Houwelingen2
1Department of Otorhinolaryngology, Head & Neck surgery, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.
The journal of prevention of Alzheimer's disease
|January 21, 2026
概括
这项研究发现,听力损失 (HL) 和阿尔茨海默病 (AD) 病理之间没有联系. 听力损失的进展也没有预测AD生物标志物,这表明其他痴呆途径.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 听力损失 (HL) 是阿尔茨海默病 (AD) 的潜在危险因素.
- 动物研究表明HL和AD之间存在双向关系.
- 这项研究研究了人类之间的关系.
研究的目的:
- 为了检查HL是否与AD病理学的变化有关.
- 为了确定AD生物标志物是否预测随后的HL进展.
主要方法:
- 在474名参与者中评估了基线Aβ42/Aβ40和p-tau217.
- 由纯色门平均值定义的HL.
- 使用粉样蛋白PET扫描并纵向重新评估HL和p-tau217.
主要成果:
- 在基线HL和AD病理标志物 (粉样蛋白PET,Aβ42/Aβ40,p-tau217) 之间没有发现相关性.
- HL进展没有预测AD病理.
- APOE4载体没有改变关联;血生物标志物与HL变化无关.
结论:
- 在听力损失和阿尔茨海默病病理学之间没有观察到双向关联.
- 这表明听力损失可能通过直接AD病理之外的其他机制导致痴呆.
- 需要进一步的研究来探索替代途径.
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35


